Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Bristol-Myers Squibb

Eliquis and Opdivo sales drive growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb
3Q Revenues:  $5.3 billion (+7)
3Q Earnings:  $856 million (-30%)
YTD Revenues: $15.3 billion (+8%)   
YTD Earnings: $3.3 billion (-6%)
Comments: Eliquis sales were up 39% in the quarter to $1.2 billion. Opdivo sales were $1.3 billion, up 38%. Yervoy sales were up 13% to $323 million. Orencia sales were up 10% to $632 million. Sprycel sales were up 8% to $509 million. Hep C Franchise sales were down 81% to $73 million. Baraclude sales were down 14% to $264 million. Sustiva Franchise sales were down 33% to $183 million and Reyataz Franchise sales were down 27% to $174 million. R&D expenses increased 36% to $1.5 billion in the quarter primarily due to the IFM Therapeutics (IFM) acquisition charge of $310 million.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters